摘要:为评估死亡供肾血栓和其诱导的受体血栓性微血管病(dir-TMA)对受体移植肾功能的影响,我们回顾性分析了33例活检病理显示微血栓的供体信息及受体预后。根据血栓累及肾小球范围是否大于50%,将33例供体分为弥漫血栓组(n=18)和局灶血栓组(n=15)。结果显示,弥漫血栓组的移植物延迟复功(DGF)发生率显著高于局灶血栓组(P=0.027),肾移植术后1个月,肾小球滤过率(eGFR)估值水平显著低于局灶血栓组(P=0.042)。此外,根据受体是否发生了dir-TMA,将33例受体进一步分为dir-TMA组(n=20)和non-dir-TMA组(n=13)。结果显示,dir-TMA 组受体肾移植术后0至9天的血小板和术后4天至1年的血红蛋白明显低于non-dir-TMA组;dir-TMA受体的DGF发生率高于non-dir-TMA组(50.0% vs. 15.4%,P=0.067),且肾移植术后1月、3月、6月和12月的肾功能均显著差于non-dir-TMA组。此外,根据受体是否接受血浆治疗,将20例发生dir-TMA的受体分为血浆治疗亚组和无血浆治疗亚组。分析表明,血浆治疗亚组受体在移植术后1月、3月、6月和12个月的肾功能均显著差于无血浆治疗亚组。综上,供肾弥漫血栓会增加受体DGF风险,但不影响移植肾功能。临床需关注发生dir-TMA受体的血小板和血红蛋白下降及肾功能恶化,有必要采用更多研究用以评估血浆疗法的效果。
摘要:The application of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) can be limited due to a lack of compatible protospacer adjacent motif (PAM) sequences in the DNA regions of interest. Recently, SpRY, a variant of Streptococcus pyogenes Cas9 (SpCas9), was reported, which nearly completely fulfils the PAM requirement. Meanwhile, PAMs for SpRY have not been well addressed. In our previous study, we developed the PAM Definition by Observable Sequence Excision (PAM-DOSE) and green fluorescent protein (GFP)-reporter system to study PAMs in human cells. Herein, we endeavored to identify the PAMs of SpRY with these two methods. The results indicated that 5'-NRN-3', 5'-NTA-3', and 5'-NCK-3' could be considered as canonical PAMs. 5'-NCA-3' and 5'-NTK-3' may serve as non-priority PAMs. At the same time, PAMs of 5'-NCC-3' and 5'-NTC-3' are not recommended for human cells. These findings provide further insights into the application of SpRY for human genome editing.
摘要:Ulcerative colitis (UC) is a chronic and recurrent inflammatory bowel disease (IBD) that has become a major gastroenterologic problem during recent decades. Numerous complicating factors are involved in UC development such as oxidative stress, inflammation, and microbiota disorder. These factors exacerbate damage to the intestinal mucosal barrier. Spirulina platensis is a commercial alga with various biological activity that is widely used as a functional ingredient in food and beverage products. However, there have been few studies on the treatment of UC using S. platensis aqueous extracts (SP), and the underlying mechanism of action of SP against UC has not yet been elucidated. Herein, we aimed to investigate the modulatory effect of SP on microbiota disorders in UC mice and clarify the underlying mechanisms by which it alleviates damage to the intestinal mucosal barrier. Dextran sulfate sodium (DSS) was used to establish a normal human colonic epithelial cell (NCM460) injury model and UC animal model. The mitochondrial membrane potential assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and staining with Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) and Hoechst 33258 were carried out to determine the effects of SP on the NCM460 cell injury model. Moreover, hematoxylin and eosin (H&E) staining, transmission electron microscopy (TEM), enzyme-linked immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (qPCR), western blot, and 16S ribosomal DNA (rDNA) sequencing were used to explore the effects and underlying mechanisms of action of SP on UC in C57BL/6 mice. In vitro studies showed that SP alleviated DSS-induced NCM460 cell injury. SP also significantly reduced the excessive generation of intracellular reactive oxygen species (ROS) and prevented mitochondrial membrane potential reduction after DSS challenge. In vivo studies indicated that SP administration could alleviate the severity of DSS-induced colonic mucosal damage compared with the control group. Inhibition of inflammation and oxidative stress was associated with increases in the activity of antioxidant enzymes and the expression of tight junction proteins (TJs) post-SP treatment. SP improved gut microbiota disorder mainly by increasing antioxidant enzyme activity and the expression of TJs in the colon. Our findings demonstrate that the protective effect of SP against UC is based on its inhibition of pro-inflammatory cytokine overproduction, inhibition of DSS-induced ROS production, and enhanced expression of antioxidant enzymes and TJs in the colonic mucosal barrier.
摘要:The application of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) can be limited due to a lack of compatible protospacer adjacent motif (PAM) sequences in the DNA regions of interest. Recently, SpRY, a variant of Streptococcus pyogenes Cas9 (SpCas9), was reported, which nearly completely fulfils the PAM requirement. Meanwhile, PAMs for SpRY have not been well addressed. In our previous study, we developed the PAM Definition by Observable Sequence Excision (PAM-DOSE) and green fluorescent protein (GFP)-reporter system to study PAMs in human cells. Herein, we endeavored to identify the PAMs of SpRY with these two methods. The results indicated that 5'-NRN-3', 5'-NTA-3', and 5'-NCK-3' could be considered as canonical PAMs. 5'-NCA-3' and 5'-NTK-3' may serve as non-priority PAMs. At the same time, PAMs of 5'-NCC-3' and 5'-NTC-3' are not recommended for human cells. These findings provide further insights into the application of SpRY for human genome editing.